MindMed voluntarily delists from Cboe Canada effective April 10, 2024; continues Nasdaq listing

Definium Therapeutics, Inc.

Voluntary delisting from Cboe Canada at market close on April 10, 2024; Cboe Canada accepted notice.
Common shares to continue trading on Nasdaq under symbol MNMD; ~95% of trading volume already on Nasdaq.
Company cites insufficient Cboe Canada volume to justify dual listing costs; savings redirected to shareholder initiatives.
Board approved delisting; no shareholder approval required as alternative market exists on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.